IN8bio(INAB) - 2024 Q2 - Quarterly Results

302406282 v3 IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress - Continues to be an industry leader in the manufacturing and the clinical advancement of gamma-delta T cells for the treatment of solid and hematologic cancers - Demonst ...